At the time of writing, Opko Health Inc [OPK] stock is trading at $0.93, up 4.49%. In order to assess the stock’s recent performance, you can check whether its short-term value is rising or falling. The OPK shares have gain 5.04% over the last week, with a monthly amount drifted -7.92%, and not seem to be holding up well over a long-time horizon.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
On 20, March 2024, Entera Bio Announces Robust Pharmacokinetic Data for First-in-Class Oral GLP-2 Peptide Tablet Treatment for Patients with Short Bowel Syndrome. In a post published today on Yahoo Finance, Pharmacokinetic Profile of Oral GLP-2 Tablets in Rats (mean±SE, n=15).
From an analyst’s perspective:
Opko Health Inc [NASDAQ: OPK] stock has seen the most recent analyst activity on June 29, 2023, when Barrington Research upgraded its rating to a Outperform but kept the price target unchanged to $2 for it. Previously, H.C. Wainwright started tracking the stock with Buy rating on December 15, 2022, and set its price target to $3. On January 24, 2022, downgrade downgraded it’s rating to Mkt Perform. Ladenburg Thalmann started tracking the stock assigning a Buy rating and suggested a price target of $7 on June 21, 2021. Piper Jaffray initiated its recommendation with a Overweight and recommended $2.50 as its price target on November 25, 2019. JP Morgan downgraded its rating to Underweight for this stock on March 02, 2018. In a note dated September 14, 2017, JP Morgan downgraded an Neutral rating on this stock.
For the past year, the stock price of Opko Health Inc fluctuated between $0.85 and $2.24. Currently, Wall Street analysts expect the stock to reach $3.5 within the next 12 months. Opko Health Inc [NASDAQ: OPK] shares were valued at $0.93 at the most recent close of the market. An investor can expect a potential return of 276.34% based on the average OPK price forecast.
Analyzing the OPK fundamentals
According to Opko Health Inc [NASDAQ:OPK], the company’s sales were 863.49M for trailing twelve months, which represents an -1.89% plunge. Gross Profit Margin for this corporation currently stands at 0.34% with Operating Profit Margin at -0.18%, Pretax Profit Margin comes in at -0.21%, and Net Profit Margin reading is -0.22%. To continue investigating profitability, this company’s Return on Assets is posted at -0.09, Equity is -0.13 and Total Capital is -0.09. An extended analysis of the company’s primary financial structure reveals a debt-to-equity ratio of0.19.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 0.8767 points at the first support level, and at 0.8233 for the second support level. However, for the 1st resistance point, the stock is sitting at 0.9967, and for the 2nd resistance point, it is at 1.0633.
Opko Health Inc [OPK] reported earnings per share of -$0.09 for its fiscal quarter that ended on 12/30/2023. Based on the Wall Street analysts’ estimates, the company was expected to report earnings of -$0.09/share, meaning a difference of $0 and a surprise factor of 0.00%. By comparison, the stated earnings for the previous quarter ended on 9/29/2023 were -$0.11 per share as compared to estimates of -$0.1 per share, a difference of -$0.01 representing a surprise of -10.00%.
Ratios To Look Out For
It is important to note that Opko Health Inc [NASDAQ:OPK] has a current ratio of 1.55. In addition, the Quick Ratio stands at 1.22 and the Cash Ratio stands at 0.48. Considering the valuation of this stock, the price to sales ratio is 0.75, the price to book ratio is 0.52.
Transactions by insiders
Recent insider trading involved FROST PHILLIP MD ET AL, CEO & Chairman, that happened on Mar 18 ’24 when 0.5 million shares were purchased. CEO & Chairman, FROST PHILLIP MD ET AL completed a deal on Mar 14 ’24 to buy 0.5 million shares. Meanwhile, CEO & Chairman FROST PHILLIP MD ET AL bought 0.5 million shares on Mar 13 ’24.
